Product Reports Resources Pricing Login Book a demo

Roivant Sciences

Biotech & Life Sciences · New York City, United States · Founded 2014 · Public via SPAC 2021

Developing transformative medicines faster by building technologies and developing talent in creative ways

Valuation $20B
Revenue $8.3M
Power Law Decacorn$10B+ valuation tier Thoroughbred$100M+ revenue

Investors

9 investors on Roivant Sciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 9 investors entered at this stage
SK Group
QVT Financial LP
NovaQuest Capital Management
RTW Investments
Viking Global Investors
SoftBank Vision Fund
Founders Fund
Dexcel Pharma
SoftBank

Roivant Sciences mafia

Startups founded by Roivant Sciences alumni

Former Roivant Sciences employees who went on to start their own companies. Sorted by Dealroom signal score.

StriveEst. 2022
Vivek RamaswamyUnited States
Signal score92
Zest HealthEst. 2022
Alex GasnerUnited States
Signal score87
Club FeastEst. 2020
Christopher MiaoUnited States
Signal score86
Proxima BioEst. 2019
Luca NaefUnited States
Signal score83
Kriya TherapeuticsEst. 2019
Shankar RamaswamyUnited States
Signal score73
The FoodhakEst. 2021
Sakshi Chhabra MittalUnited Kingdom
Signal score63
Tourmaline BioEst. 2022
Sandeep KulkarniUnited States
Signal score62
ZipBioEst. 2022
Roee FarberUnited States
Signal score62
LokavantEst. 2020
JAJohn AlfanoUnited States
Signal score56
MiraeEst. 2026
Anuj PatelUnited States
Signal score44

Book a demo to explore the full alumni network →

Global footprint

Where Roivant Sciences has talent and traffic

Workforce by country
4 countries with
team presence
🇺🇸 United States96.7%
🇨🇭 Switzerland2.2%
🇮🇱 Israel0.5%
🇧🇪 Belgium0.5%
4 countries shown
Web traffic by country
20K monthly visits
across markets
🇺🇸 United States78%
🇬🇧 United Kingdom13%
🇮🇳 India4.5%
🏳️ Korea4%
🏳️ Republic of1.5%
Top 5 markets shown

Talent graph

The shape of Roivant Sciences's talent

Dealroom maps Roivant Sciences's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

15 standout operatorsDealroom-flagged across the org
1 AI specialistpinpointed by name
224 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Roivant Sciences's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$49M patent portfolio · 47 active families

Estimated portfolio value
$49M
0.24% of market cap · 2.2× smaller than top peer Celltrion ($107M)
47 active patent families
Where Roivant Sciences innovates Pharmaceutical SubstancesPharmaceutical drugPharmacologyBiochemistryBiophysics

Where Roivant Sciences concentrates vs peers

Each axis is a top-10 topic across Roivant Sciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Roivant Sciences's 17 investments and acquisitions.

Every disclosed deal where Roivant Sciences appeared as a backer or acquirer, 2016–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

17 deals across Roivant Sciences's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Roivant Sciences deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Roivant Sciences's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        17 of 17 deals

        Market sentiment

        What the market is saying about Roivant Sciences

        An AI-synthesized read of the highest-engagement posts about Roivant Sciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Roivant Sciences on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles